order-form-photo
Only qualified healthcare providers may order

Trusight Tumor 170 (TST170)

Every patient is unique, and so is their cancer. The constellation of mutations present in cancer cells plays a role in the patient’s response to therapy. Therefore, it is crucial to understand the pattern of mutations in order to select the most appropriate treatment for each person’s cancer. The TruSight Tumor 170 test is a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, including assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications. This comprehensive test helps providers diagnose and treat each unique cancer to improve patient outcomes.

Reporting

  • The TruSight Tumor 170 test includes standardized analytics and reporting of multiple variant types in a single assay, including small nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), splice variants, fusions, and emerging immunotherapy biomarkers that rely on analysis of multiple genomic loci, such as tumor mutational burden (TMB) and microsatellite instability (MSI). Pathology services and additional interpretation and consultation by a board-certified Molecular Pathologist is also available for this test.
  • Sample Report

Turnaround Time (TAT)

  • Turnaround time from sample receipt to final report is 14 days.

Specimen Requirements

  • FFPE blocks (preferred): select a block that is representative of the tumor and has a minimum of ~20% tumor cellularity (by nuclei).
  • Slides: submit 10 consecutive, unstained slides of 8-10 μm. Also submit an H&E stained slide if available, and if not available, an 11th slide for staining.
  • Extracted DNA/RNA: submit a minimum of 250 ng at ≥10 ng/μL of purified DNA, and a minimum of 200 ng at ≥10 ng/μl purified RNA. Specimens should be submitted in a screw cap tube. AllPrep kit preferred for DNA/RNA extraction from FFPE.
  • Rejection criteria: Blocks or slides with <20% tumor cellularity may be rejected if microdissection cannot sufficiently provide adequate tumor material for analysis. Specimens with significant tumor necrosis, improper fixation, or treatment with acid decalcification, as well as broken slides, will be rejected.

This test(s) was developed, and performance characteristics were determined by the HudsonAlpha Clinical Services Lab, LLC. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. These tests are used for clinical purposes, and therefore validation was done as required under the requirements of the Clinical Laboratory Improvement Act (CLIA) of 1988. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The chance of a false negative or a false-positive result due to laboratory error cannot be completely excluded. These results should not be regarded as investigational or for research.